DrugPatentWatch Database Preview
Drugs in Development Information for Prexasertib
» See Plans and Pricing
What is the development status for investigational drug Prexasertib?
Prexasertib is an investigational drug.
There have been 14 clinical trials for Prexasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Neoplasms, Neoplasm Metastasis, and Colorectal Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Memorial Sloan Kettering Cancer Center.
There are three US patents protecting this investigational drug and sixty-eight international patents.
Summary for Prexasertib
| US Patents | 3 |
| International Patents | 68 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 68 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-10-01) |
| Vendors | 31 |
Recent Clinical Trials for Prexasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Memorial Sloan Kettering Cancer Center | Phase 1/Phase 2 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Eli Lilly and Company | Phase 1 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | St. Jude Children's Research Hospital | Phase 1 |
Clinical Trial Summary for Prexasertib
Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib
US Patents for Prexasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Prexasertib | Start Trial | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate | Eli Lilly and Company (Indianapolis, IN) | Start Trial |
| Prexasertib | Start Trial | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) | Start Trial |
| Prexasertib | Start Trial | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | Eli Lilly and Company (Indianapolis, IN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Prexasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Prexasertib | Argentina | AR106772 | 2035-12-07 | Start Trial |
| Prexasertib | Australia | AU2016367041 | 2035-12-07 | Start Trial |
| Prexasertib | Brazil | BR112018008398 | 2035-12-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
